Moderna faces significant financial and regulatory challenges in early 2026 but has secured several strategic wins that could stabilize its future. The company announced it will pay up to $2.25 billion to resolve patent infringement claims with Arbutus Biopharma Corp. and Genevant Sciences GmbH regarding...
Moderna (MRNA) is approaching its Q2 2026 earnings report due on July 31, following a streak of five consecutive quarterly beats. The company recently reported Q1 revenue of $389 million, significantly beating the consensus estimate of $236.36 million and showing year-over-year growth. Market sentiment is...
Moderna (NASDAQ: MRNA) is scheduled to announce its Q2 2026 earnings results before the market opens on Friday, July 31st, with a conference call set for 8:00 AM ET. Analysts currently anticipate a loss of $2.00 per share and revenue of approximately $103 million for...
Fifth Third Bancorp significantly increased its stake in Moderna, Inc. (MRNA) by 157.5% in the first quarter, purchasing an additional 36,912 shares to hold a total position of 60,341 shares valued at $3.065 million. Other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors...
Moderna Inc.'s mRNA-based influenza vaccine has received a recommendation for approval from an external advisory committee of the US Food and Drug Administration (FDA). This development marks a significant positive milestone for the biotechnology company, which has faced scrutiny regarding this specific product line at...
